Renal Sympathetic Denervation for the Treatment of Resistant Hypertension with Chronic Renal Failure: First-in-man Experience.
Luo Di,Zhang Xin,Lu Cheng-zhi
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20121364
IF: 6.133
2013-01-01
Chinese Medical Journal
Abstract:A 39-year-old man with resistant hypertension, presented with headache and dizziness at the emergency department on January 6, 2012. The patient had a history of hypertension for 3 years, his highest blood pressure was 250/110 mmHg, and he was taking antihypertensive medication regimens for at least 6 months. A mitral replacement by bioprosthetic valve had been implanted 6 months before. The patient was in chronic renal failure (CRF) uremia, maintenance of which he underwent the standard hemodialysis treatment three times a week for 6 months. Hemodialysis was done using anti-seepage, bicarbonate dialysate, the German Fresenius 4008S dialysis machine, with a blood flow of an average of 240 ml/min, dialysis flow 500 ml/min, 4 hours/time. Coronary artery disease, secondary hypertension, and type 2 diabetes mellitus were excluded. After admission, this patient was subjected to ambulatory blood pressure monitoring and adrenal computed tomography. Estimated glomerular filtration rate (eGFR) was calculated by simple modification of diet in renal disease (MDRD) equation for Chinese.1 All blood samples were taken a day before dialysis in order to exclude interference. According to the poor effects of medication on hypertension, renal sympathetic denervation (RSD) was recommended. RSD, a novel catheter-based approach that wipes out renal sympathetic nerves by radiofrequency ablation technology, has shown magical antihypertensive effects against resistant hypertension.2 The patient signed his informed consent before surgery. The patient had no history of previous renal artery intervention, including balloon angioplasty or stenting. RSD was performed on January 16, 2012. Renal arteriography was performed via the brachial artery in his fossa cubitalia. The results showed one main renal artery in each kidney, and no obvious stenosis in either renal artery. The treatment catheter lining the radiofrequency equipment (IBI-1500T, IBM, USA) was given through the way just outline approach to each renal artery. Six ablations at 8 weeks for 2 minutes were performed in bilateral renal arteries. Catheter tip impedance and temperature were constantly monitored. Fentanyi citrate and morphine were used during the surgery for visceral pain. Review of renal arteriography showed no notable difference after RSD. After ablation, BP dropped to 180/80 mmHg. On day 3 after admission, we rechecked the patient's renal function and observed that blood urea nitrogen (BUN) was 14.34 mmol/L, creatinine (Cr) 595.9 mmol/L, uric acid (UA) 172.4 μmol/L, and eGFR 12.05 ml˙min-1˙1.73 m-2, without any complication. The patient was discharged from the hospital 4 days after RSD with amiodipine besylate (5 mg/d), irbesartan and hydrochlorothiazide (162.5 mg/d), and arotinolol (10 mg/d) without intravenous drug use to keep the blood pressure (BP) at 160/80 mmHg. Maintain hemodialysis treatment was done 3 times a week. All blood tests were repeated at 1 month and 3 months after renal denervation, ambulatory blood pressure monitoring was retested at 3 months, and all measurements were summarized in Table 1.Table 1: Clinical characteristic at baseline, 1 month and 3 months after renal denervationAfter the RSD, decreases in office systolic BP (SBP) and diastolic BP (DBP) -45/-5 mmHg and -55/-5 mmHg for 1 and 3 months, respectively, were observed. And 3 months after RSD, the ambulatory blood pressure monitoring was reviewed. Compared to the baseline, the means reductions at 3 months in SBP were (58±14) mmHg, (62±12) mmHg, (51±13) mmHg for 24 hours, day time, and night time, respectively. Considering DBP, the decline were (7±8) mmHg, (5±9) mmHg, and (9±4) mmHg for 24 hours, day time, and night time, respectively. The 24-hour BPs were significantly lower at 3 months follow-up than baseline (95% CI 52.5-64.2, P <0.01; 95% CI 3.3-10.0, P <0.01) for SBP and DBP. Patient lifestyle and cholesterol-lowering drug intake did not change during the 3-month follow-up, The eGFR remained stable at the higher level comparing to the baseline with a change of 4.55 ml˙min-1 ˙1.73 m-2 and 4.70 ml˙min-1˙1.73 m-2 for 1 month and 3 months, respectively. The levels of fasting plasma glucose, lipoprotein, weight, and body mass index at baseline and 3 months after are listed in Table 1. For echocardiogram, the new iE33 xMATRIX echo system with X5-1 transducer was used. The left ventricular ejection fraction (LVEF) was 55%, left ventricular end-diastolic volume (LVEDD) was 58 mm at baseline; while 3 months after surgery, the indicator turns out to be 58% and 53 mm, which were much lesser than before. Renal ultrasound and Doppler, renal artery computed tomography angiography (CTA) showed no significant renal morphological changes. The patient with CRF underwent RSD without procedure-related complications. Recently a series of studies seemed to indicate the safety and validity of the catheter-based renal denervation in managing treatment resistant hypertension. Rippy et al3 studied a patients treatment with RSD whose renal primarily fibrosis was replaced by nerve fascicles with fibrous connective tissue, and thickening of the epineurium and perineurium. No significant smooth muscle hyperplasia or inflammatory components were observed. Hering et al4 performed bilateral renal denervation in 15 patients with resistant hypertension and mean eGFR 31 ml˙min-1˙1.73 m-2. This study suggests a favorable short-term safety profile and beneficial BP effects of RSD in patients with stages 3-4 CKD and resistant hypertension. Not only associated with hypertension and its progression, renal sympathetic hyperactivity but also play an important role in the pathogenesis of chronic renal failure, which directly caused the reduction of the renal arterial perfusion, water-sodium retention, albuminuria, glomerulosclerosis, and elevation of blood pressure by vasocontractors and rennin-angiotensin-aldosterone system over reactivity. The afferent impulses from injured kidney may activate areas of the brain involved in the noradrenergic regulation of blood pressure and largely contribute to the development and maintenance of hypertension. Cui et al5 analyzed more than 10 000 hypertensive patients and found that the hypertensive target organ damage is high in older Chinese patients, and the eGFR was independently associated with CKD. Chronic renal failure may be accompanied by reversible sympathetic activation, which appears to be mediated by an afferent signal arising in the failing kidneys. Sympathetic nerve overactivity is associated with the mortality and cardiovascular outcomes in end-stage renal disease. In this case, the patient with CRF (uremia) who took hemodialysis treatment suffered from the problem of high blood pressure. Before admission he had been on full-dose taking five different antihypertensive drugs for 6 months while the BP level was still up to 200/100 mmHg or much higher. After the surgery, the patient's clinical status of chronic heart failure, the reaction to the hemodialysis, and the most important BPs level were improved. Though two pills of antihypertensive drug are able to maintain the BP level at 150/80 mmHg, and no procedure-related complications were observed, a long-term, large-scale study is needed. The sympathetic nervous system is a major pathophysiological symbol of both resistant hypertension and chronic renal failure. RSD is feasible even in CRF patients. Randomized controlled trials are urgently needed to study the effects of RSD in patients with CRF.